Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE: Iruplinalkib vs Crizotinib in ALK+ NSCLC
NCT04632758Phase 3Active, not recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of iruplinalkib in anaplastic lymphoma kinase positive non-small cell lung cancer, sponsored by Qilu Pharmaceutical. Started Jun 2019; status: active, not recruiting.
02
Drugs
iruplinalkib
03
Conditions
anaplastic lymphoma kinase positive non-small cell lung cancer
Beyond the preview
Go deeper on NCT04632758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632758.